Jiménez-Luévano MÁ, Lerma-Díaz JM, Hernández-Flores G, Jiménez-Partida MÁ, Bravo-Cuellar A

Language: English
References: 21
Page: 248-255
PDF size: 121.88 Kb.

ABSTRACT

Background and aim. The commonly accepted treatment for hepatitis C virus (HCV) infection, pegylated interferon alpha (PEG INF-alpha) and ribavirin, leads to 50-60% of sustained virological response (SVR). On the other hand, pentoxifylline (PTX) possesses antiviral and hepatoprotector properties. Aim. To investigate whether the addition of PTX to conventional hepatitis C treatment increases SVR. Material and methods. Seventy two patients of both genders were studied in a randomized fashion; the diagnosis of chronic HCV infection was made according to clinical and laboratory criteria and histopathologically classified according to METAVIR scoring system criteria. HCV viral load was tested by PCR, baseline, and after 6 months of treatment, as well as anti-HCV, anti-hepatitis B virus , and anti-human immunodeficiency virus antibodies by enzyme-linked immunosorbent assay. During 48 weeks, control group patients were treated with PEG INFalpha-2a plus ribavirin. PTX was administered to Experimental Group patients prior to the treatment. Results. Demographic data were similar in both groups. Experimental- and control-group subjects were at F2 and F3 states according to the METAVIR classification. The most common HCV genotypes were 1a and 1b (39% in the control group in each case, and 42% in the experimental group in each case). At the end of the study, hepatic enzymes and viral load decreased in both groups to similar values. SVR in the experimental group increased significantly (p ‹ 0.05) when compared with standard therapy alone. Conclusion. Addition of PTX to conventional chronic hepatitis C treatment may increase the percentage of patients with SVR.

REFERENCES

1. Lavanchy D. Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol 2008; 22: 991-1008.

2. Czepiel J, Biesiada G, Mach T. Viral hepatitis C. Pol Arch Med Wewn 2008; 118: 734-40.

3. García-Montalvo BM, Galguera-Colorado PL. Distribution of hepatitis C virus genotypes, risk factors and liver disease in patients from Yucatan, Mexico. Ann Hepatol 2008; 7: 345-9.

4. Feuerstadt P, Bunim AL, García H, Karlitz JJ, Massoumi H, Thosani AJ, Pellecchia A, et al. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology 2011; 51: 1137-43.

5. Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, Wedemeyer H, Sarrazin C, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009; 16: 75-90.

6. Simula MP, De Re V. Hepatitis C virus-induced oxidative stress and mitochondrial dysfunction: a focus on recent advances in proteomics. Proteomics Clin Appl 2010; 4: 782-93.

7. Olleros ML, Vesin D, Fotio AL, Santiago-Raber ML, Tauzin S, Szymkowski DE, García I. Soluble TNF, but not membrane TNF, is critical in LPS-induced hepatitis. J Hepatol 2010; 53: 1059-68.

8. Petrowsky H, Breitenstein S, Slankamenac K, Vetter D, Lehmann K, Heinrich S, DeOliveira ML, et al. Effects of pentoxifylline on liver regeneration: a double-blinded, randomized, controlled trial in 101 patients undergoing major liver resection. Ann Surg 2010; 252: 813-22.

9. Gupta SK, Johnson RM, Mather KJ, Clauss M, Rehman J, Saha C, Desta Z, et al. Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: a pilot study. AIDS 2010; 24: 1377-80.

10. Assem M, Yousri M. Impact of pentoxifylline and vitamin E on ribavirin-induced haemolytic anaemia in chronic hepatitis C patients: an Egyptian survey [Abstract]. Int J Hepatol 2011; 2011: 530949.

11. Hepgul G, Tanrikulu S, Unalp HR, Akguner T, Erbil Y, Olgac V, Ademoglu E. Preventive effect of pentoxifylline on acute radiation damage via antioxidant and anti-inflammatory pathways. Dig Dis Sci 2010; 55: 617-25.

12. Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis [Abstract]. BMJ 2011; 340: b5569.

13. Cross TJ, Calvaruso V, Foxton MR, Manousou P, Quaglia A, Grillo F, Dhillon AP, et al. A simple, noninvasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation. J Viral Hepat 2010; 17: 640-9.

14. Kayadibi H, Gultepe M, Yasar B, Ince AT, Ozcan O, Ipcioglu OM, Kurdas OO, et al. Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: a surrogate marker to distinguish steatohepatitis from simple steatosis. Dig Dis Sci 2009; 54: 1764-71.

15. Okazaki K, Nishiyama Y, Saitou T, Shibata N, Yamamoto C, Oosaga J, Tanaka M, et al. Fundamental evaluation of HCV core antigen method comparison with Cobas Amplicor HCV monitor v2.0 (high range method). Rinsho Byori 2008; 56: 95-100.

16. Taye A, El-Moselhy MA, Hassan MK, Ibrahim HM, Mohammed AF. Hepatoprotective effect of pentoxifylline against Dgalactosamine- induced hepatotoxicity in rats. Ann Hepatol 2009; 8: 364-70.

17. Lee YM, Sutedja DS, Wai CT, Dan YY, Aung MO, Zhou L, Cheng CL, et al. A randomized controlled pilot study of pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2008; 2: 196-201.

18. Mihaila RG, Nedelcu L, Fratila O, Rezi EC, Domnariu C, Deac M. Effects of lovastatin and pentoxifylline in nonalcoholic steatohepatitis. Hepatogastroenterology 2009; 56: 1117-21.

19. Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009: CD007339.

20. Jiménez-Luévano MA, Cortés-Nuño S, Rocha-López AN, Cervantes-Rodríguez MTG, Bravo-Cuéllar A, Franco-Topete R, Abascal-Medina CG. La pentoxifilina en la hepatitis fulminante: reporte de dos casos. Rev Biomed 2009: 20: 33-9.

21. Wystrychowski A, Wystrychowski W, Krol P, Obuchowicz E, Cierpka L, Wiecek A. Pentoxifylline augments fastinginduced nephroprotection in acute ischemic kidney injury in rats. Transplant Proc 2009; 41: 2992-3.